Slotsmarken 18, 2. th.
Hørsholm 2970
Denmark
45 41 92 25 25
https://www.pharmaequitygroup.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Thomas Kaas Selsø | Chief Executive Officer | N/D | N/D | 1973 |
Lars Skriver | Chief Operations Officer | N/D | N/D | N/D |
Prof. Lars Otto Uttenthal | Chief Scientific Officer | N/D | N/D | N/D |
Dr. Christopher M. Burton | Chief Medical Officer | N/D | N/D | 1973 |
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark.
L'ISS Governance QualityScore di Pharma Equity Group A/S al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.